9.08亿元！广药集团入主达安基因

Core Viewpoint - Da An Gene, a leading company in genetic testing, is set to be acquired by Guangzhou Pharmaceutical Group, which is seen as a potential rescue for the struggling company [1][6]. Group 1: Acquisition Details - Guangzhou Pharmaceutical Group will acquire 16.63% of Da An Gene's shares through Guangzhou Jinkong Group and Guangzhou Health Industry Investment, along with an additional 10% stake at a price of 6.47 yuan per share, totaling 9.08 billion yuan [3]. - Post-acquisition, Guangzhou Pharmaceutical Group will control approximately 26.63% of Da An Gene, while Guangzhou Jinkong Group will retain a 5% stake [3]. - The transaction will not change the actual controller of Da An Gene, which remains under the control of the Guangzhou Municipal Government [3]. Group 2: Financial Performance - Da An Gene experienced a dramatic decline in revenue and net profit, with revenues dropping from 120.5 billion yuan in 2022 to 8.53 billion yuan in 2024, and net profit plummeting from 54.28 billion yuan to a loss of 9.39 billion yuan in the same period [4]. - In the first three quarters of 2025, Da An Gene reported revenues of 5.04 billion yuan, a year-on-year decrease of 14.8%, and a net loss of 1.51 billion yuan, despite a 69.9% increase in losses [5]. - The company has significantly reduced R&D spending by nearly 30%, while marketing expenses surged by 70% [5]. Group 3: Challenges and Management Changes - Da An Gene has faced internal turmoil, including a three-year boardroom conflict that resulted in the exit of the founding technical team and the takeover by new financial stakeholders [5][9]. - The company has also been involved in a corruption scandal related to hospital testing departments and has laid off over 60% of its workforce [5]. - The recent acquisition by Guangzhou Pharmaceutical Group may lead to further personnel changes, raising concerns about the expertise of new management in the IVD sector [6][8]. Group 4: Strategic Outlook - Guangzhou Pharmaceutical Group aims to create a full-chain integration of "testing-diagnosis-drugs" through the acquisition, as its medical device segment has contributed only 1% to its revenue [7]. - There are doubts about the integration of Da An Gene's IVD-focused business with Guangzhou Pharmaceutical Group's existing low-margin medical device operations, which may complicate future collaboration [8]. - The historical context of Guangzhou Pharmaceutical Group's previous unsuccessful ventures into the IVD market raises skepticism about the potential success of this acquisition [9].